# FDA recall D-0154-2018

> **ALLERGAN** · Class II · drug recall initiated 2017-12-04.

## Product

Viokace (pancrelipase) tablets, 20,880 USP units, 100-count bottle, Rx only, Distributed by; Allergan USA Inc., Irvine, CA 92612, Manufactured in Canada, NDC 58914-117-10

## Reason for recall

Subpotent Drug: One lot of Viokace is being recalled since product stability testing results did not meet the specifications for enzyme profile.

## Distribution

U.S.A. nationwide

## Key facts

- **Recall number:** D-0154-2018
- **Recalling firm:** ALLERGAN
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2017-12-04
- **Report date:** 2018-01-17
- **Termination date:** 2019-06-20

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Madison, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0154-2018

## Citation

> AI Analytics. FDA recall D-0154-2018. Retrieved 2026-06-23 from https://api.ai-analytics.org/recall/D-0154-2018. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*